Prevalence of symptomatic gastro-oesophageal reflux disease in Japanese patients with peptic ulcer disease after eradication of Helicobacter pylori infection

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 1, 2004, Pages 107-111

  Yamamori, K ^a   Fujiwara, Y ^a   Shiba, M ^a   Watanabe, T ^a   Tominaga, K ^a   Oshitani, N ^a   Matsumoto, T ^a   Higuchi, K ^a   Arakawa, T ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; OMEPRAZOLE; PEPSINOGEN; RABEPRAZOLE;

ADOLESCENT; ADULT; AGED; ATROPHIC GASTRITIS; BODY MASS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRINKING BEHAVIOR; DUODENUM ULCER; ERADICATION THERAPY; FEMALE; GASTROESOPHAGEAL REFLUX; GENDER; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIATUS HERNIA; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RETROSPECTIVE STUDY; SMOKING HABIT; STOMACH ULCER;

EID: 4344689111     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01973.x     Document Type: Conference Paper

References (23)

1. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori Lancet 1988; 2: 1437-42.
2. Graham DY, Lew GM, Evans DG, Evans DJ Jr, Klein PD. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med 1991; 115: 266-9.
3. Van der Hulst RW, Rauws EA, Koycu B, et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology 1997; 113: 1082-6.
4. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7.
5. Hamada H, Haruma K, Mihara M, et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14: 729-35.
6. Fujiwara Y, Higuchi K, Arafa UA, et al. Long-term effect of Helicobacter pylori eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease. Hepatogastroenterology 2002; 49: 1298-302.
7. Befrits R, Sjostedt S, Odman B, Sorngard H, Lindberg G. Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. Helicobacter 2000; 5: 202-5.
8. McColl KE, Dickson A, El-Nujumi A, El-Omar E, Kelman A. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 101-5.
9. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
10. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 45-51.
11. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990; 335: 205-8.
12. Dent J. Gastro-oesophageal reflux disease. Digestion 1998; 59: 433-45.
13. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl 1993; 199: 18-21.
14. Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 252-8.
15. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
16. Miki K, Ichinose M, Kakei N, et al. The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer. Adv Exp Med Biol 1995; 362: 139-43.
17. Watanabe Y, Kurata JH, Mizuno S, et al. Helicobacter pylori infection and gastric cancer. A nested case-control study in a rural area of Japan. Dig Dis Sci 1997; 42: 1383-7.
18. Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese-population. Gastroenterology 1992; 102: 760-6.
19. Amano K, Adachi K, Katsube T, Watanabe M, Kinoshita Y. Role of hiatus hernia and gastric mucosal atrophy in the development of reflux esophagitis in the elderly. J Gastroenterol Hepatol 2001; 16: 132-6.
20. Kim DY, Baek JY. The comparison of histologic gastritis in patients with duodenal ulcer, chronic gastritis, gastric ulcer and gastric cancer. Yonsei Med J 1999; 40: 14-9.
21. Iijima K, Ohara S, Sekine H, et al. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut 2000; 46: 20-6.
22. Fujishiro H, Adachi K, Kawamura A, et al. Influence of Helicobacter pylori infection on the prevalence of reflux esophagitis in Japanese patients. J Gastroenterol Hepatol 2001; 16: 1217-21.
23. Richter JE. Ambulatory esophageal pH monitoring. Am J Med 1997; 103: 130S-134S.